We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.02 | 0.92% | 2.20 | 2.11 | 2.25 | 2.20 | 2.20 | 2.20 | 424,396 | 08:44:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.91 | 7.27M |
TIDMIMM
RNS Number : 8456K
Immupharma PLC
12 July 2017
12 July 2017
Grant of Options
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces the approval of the grant of options over 1,400,000 ordinary shares of 10p each ("Ordinary Shares") to certain of its non-executive Directors representing 1.06% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis. The exercise price for these options is 56.75p pence being the closing middle market share price on 11 July 2017. The options will vest after three years and are exercisable between three and ten years from the date of grant.
The amount of options granted to non-executive Directors are summarised in the following table:
Director Ordinary Shares under Option ----------------- ---------------- Tim McCarthy 1,000,000 ----------------- ---------------- Franco di Muzio 200,000 ----------------- ---------------- Stephane Mery 200,000 ----------------- ----------------
Following this grant of all options on the above date, the total number of share options outstanding will be 8,233,850 representing 6.2% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis.
Messrs McCarthy, di Muzio and Mery currently have the following interests in issued Ordinary Shares:
Director Number of % of issued share Ordinary Shares capital at 11 July 2017 ----------------- ----------------- ----------------- Tim McCarthy 38,462 0.03% ----------------- ----------------- ----------------- Franco di Muzio 99,412 0.08% ----------------- ----------------- ----------------- Stephane Mery 21,490 0.02% ----------------- ----------------- -----------------
Following the grant of the options referred to above, Messrs McCarthy, di Muzio and Mery will have the following interests in options over the Company's Ordinary Shares:
Director Number of Exercise Price Expiry Date Ordinary Shares under option -------------- -------------- -------------- ----------- Tim McCarthy 500,000 43.88p 02.06.2026 1,000,000 56.75p 12.07.2027 -------------- -------------- -------------- ----------- Franco di 100,000 76.80p 31.07.2017 Muzio 100,000 86.50p 04.02.2019 100,000 43.88p 02.06.2026 200,000 56.75p 12.07.2027 -------------- -------------- -------------- ----------- Stephane Mery 100,000 43.88p 02.06.2026 200,000 56.75p 12.07.2027 -------------- -------------- -------------- -----------
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
Ends
For further information please contact: + 44 (0) 20 ImmuPharma plc (www.immupharma.org) 7152 4080 Tim McCarthy, Chairman Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 Twitter: @immupharma 413496 Northland Capital Partners Limited (NOMAD & Broker) Patrick Claridge, David Hignell, Jamie Spotswood, Corporate Finance +44 (0)20 3861 Rob Rees, Corporate Broking 6625
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHRTMLTMBABMMR
(END) Dow Jones Newswires
July 12, 2017 06:00 ET (10:00 GMT)
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions